Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock: Insider Bruce Cozadd Sells 68,808 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 68,808 shares of the firm’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $235.95, for a total value of $16,235,247.60. Following the completion of the transaction, the director owned 357,567 shares of the company’s stock, valued at approximately $84,367,933.65. This represents a 16.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jazz Pharmaceuticals Stock Up 1.1%

JAZZ stock opened at $248.24 on Thursday. The stock has a 50-day simple moving average of $229.35 and a two-hundred day simple moving average of $218.88. Jazz Pharmaceuticals PLC has a twelve month low of $136.27 and a twelve month high of $266.38. The firm has a market capitalization of $15.93 billion, a PE ratio of 21.76, a PEG ratio of 0.45 and a beta of 0.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the firm posted $8.13 earnings per share. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. USA Financial Formulas purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at about $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth approximately $32,000. Ameritas Advisory Services LLC purchased a new position in Jazz Pharmaceuticals in the 2nd quarter worth approximately $47,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Jazz Pharmaceuticals in the 2nd quarter worth approximately $61,000. Finally, Elevation Wealth Partners LLC lifted its position in Jazz Pharmaceuticals by 156.4% in the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock valued at $60,000 after purchasing an additional 158 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of several research analyst reports. Needham & Company LLC upped their price objective on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. UBS Group upped their target price on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Weiss Ratings cut shares of Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, October 28th. Deutsche Bank increased their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. Finally, Morgan Stanley lifted their price target on shares of Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $293.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.